Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.68 |
| ▸ | KDM5A | P29375 | 1/20 | 0.68 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.68 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.68 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.62 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352104 | 0.94 | ALOX5 (0.70) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL16341566 | 0.93 | ALOX5 (0.68) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL16352102 | 0.90 | ALOX5 (0.72) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL16341565 | 0.83 | ALOX5 (0.65) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL10691673 | 0.82 | ALOX5 (0.90) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL16352103 | 0.81 | ALOX5 (0.52) | ALOX5 | |
| SCHEMBL16322681 | 0.80 | ALOX5 (0.51) | ALOX5 | |
| SCHEMBL28147120 | 0.79 | ALOX5 (0.72) | KDM4AKDM5AKDM4CPHF8KDM2A | |
| SCHEMBL8949998 | 0.79 | S1PR2 (0.75) | S1PR2S1PR4S1PR1S1PR3MAPT | |
| SCHEMBL3208019 | 0.79 | S1PR2 (0.75) | S1PR2S1PR4S1PR1S1PR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089349-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015084721-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | KDM4A 3863/4885KDM5A 3609/4885KDM4C 4487/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | KDM4A 4640/4885KDM5A 4638/4885KDM4C 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.